ArriVent BioPharma, Inc. recently announced that its Phase 3 FURVENT trial of firmonertinib, aimed at treating non-small cell lung cancer (NSCLC), did not meet its primary endpoint of progression-free survival (PFS). This outcome raises critical questions about the drug's future and the company's strategic direction.
On October 6, 2026, the company issued a press release detailing the results of the trial, which evaluated firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations. Despite not achieving its primary endpoint, the trial did show some clinical benefits with secondary endpoints, including PFS as assessed by investigators and confirmed objective response rates.
ArriVent BioPharma, headquartered in Newtown Square, Pennsylvania, operates under the Standard Industrial Classification of Pharmaceutical Preparations (SIC 2834). The company is listed on the Nasdaq under the ticker AVBP and is categorized as an emerging growth company.
The filing indicates that the safety profile of firmonertinib remained consistent with earlier studies, with no new safety signals reported. However, the disappointing results were highlighted by Dr. Bing Yao, Chairman and CEO of ArriVent, who expressed concern for patients needing effective treatment options. “These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options,” he stated.
Key results from the trial showed that the median PFS for firmonertinib at 240 mg was 11.0 months, while the control group had a median PFS of 9.5 months. The p-value for the comparison was 0.0654, indicating a trend toward improvement but not statistically significant. The confirmed objective response rates were reported at 60% for the 240 mg dose and 35% for the 160 mg dose, compared to 33% for the control group.
As ArriVent evaluates the full dataset from the FURVENT trial, the implications of these results extend beyond the company itself. The pharmaceutical industry, particularly in the oncology sector, is continuously challenged to deliver effective treatments for complex diseases like lung cancer. Competitors in this space may now reassess their own drug development strategies in light of ArriVent's findings.
Looking ahead, it remains unclear what specific steps ArriVent will take next regarding firmonertinib. The filing does not provide detailed information on future filings or potential votes related to this trial's outcome. The company is expected to analyze the complete dataset to determine the most appropriate development path for the drug.